LTRN – Lantern Pharma Inc
Lantern Pharma Inc.LTRN
$3.35Name : Lantern Pharma Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $36,128,744.00
EPSttm : -1.84
Lantern Pharma Inc.
$3.35
0.45%$0.015Float Short %
3.14
Margin Of Safety %
Put/Call OI Ratio
0.17
EPS Next Q Diff
EPS Last/This Y
0.1
EPS This/Next Y
0.28
Price
3.43
Target Price
22
Analyst Recom
1
Performance Q
-11.83
Relative Volume
1.21
Beta
1.54
Ticker: LTRN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-05-07 | LTRN | 4.36 | 0.18 | 0.00 | 422 |
| 2025-05-08 | LTRN | 3.85 | 0.18 | 0.00 | 422 |
| 2025-05-09 | LTRN | 3.98 | 0.18 | 0.00 | 421 |
| 2025-05-12 | LTRN | 4.12 | 0.16 | 0.01 | 455 |
| 2025-05-13 | LTRN | 4.1 | 0.12 | 0.00 | 588 |
| 2025-05-14 | LTRN | 4.06 | 0.12 | 0.00 | 594 |
| 2025-05-15 | LTRN | 3.92 | 0.12 | 0.00 | 597 |
| 2025-05-16 | LTRN | 3.34 | 0.06 | 2.48 | 567 |
| 2025-05-19 | LTRN | 3.56 | 0.20 | 3.50 | 443 |
| 2025-05-20 | LTRN | 3.47 | 0.20 | 3.50 | 443 |
| 2025-05-21 | LTRN | 3.32 | 0.22 | 5.00 | 451 |
| 2025-05-22 | LTRN | 3.31 | 0.21 | 0.00 | 455 |
| 2025-05-23 | LTRN | 3.26 | 0.21 | 0.00 | 455 |
| 2025-05-27 | LTRN | 2.9 | 0.18 | 999.99 | 523 |
| 2025-05-28 | LTRN | 2.88 | 0.18 | 0.00 | 527 |
| 2025-05-29 | LTRN | 3.11 | 0.18 | 0.00 | 527 |
| 2025-05-30 | LTRN | 3.12 | 0.18 | 0.00 | 528 |
| 2025-06-02 | LTRN | 3.19 | 0.18 | 0.00 | 529 |
| 2025-06-03 | LTRN | 3.22 | 0.17 | 0.00 | 549 |
| 2025-06-04 | LTRN | 3.34 | 0.17 | 0.00 | 550 |
| 2025-06-05 | LTRN | 3.42 | 0.17 | 50.00 | 549 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-05-07 | LTRN | 4.34 | 3.9 | - | -1.99 |
| 2025-05-08 | LTRN | 3.91 | 3.9 | - | -1.99 |
| 2025-05-09 | LTRN | 3.98 | 3.9 | - | -1.99 |
| 2025-05-12 | LTRN | 4.11 | 3.9 | - | -1.99 |
| 2025-05-13 | LTRN | 4.11 | 3.9 | - | -1.99 |
| 2025-05-14 | LTRN | 4.15 | 3.9 | - | -1.99 |
| 2025-05-15 | LTRN | 3.87 | 3.9 | - | -1.99 |
| 2025-05-16 | LTRN | 3.41 | 3.9 | - | -1.99 |
| 2025-05-19 | LTRN | 3.59 | 3.9 | - | -1.84 |
| 2025-05-20 | LTRN | 3.48 | - | - | -1.84 |
| 2025-05-21 | LTRN | 3.37 | - | - | -1.84 |
| 2025-05-22 | LTRN | 3.32 | - | - | -1.84 |
| 2025-05-23 | LTRN | 3.21 | - | - | -1.84 |
| 2025-05-27 | LTRN | 2.90 | - | - | -1.82 |
| 2025-05-28 | LTRN | 2.89 | - | - | -1.82 |
| 2025-05-29 | LTRN | 3.09 | - | - | -1.82 |
| 2025-05-30 | LTRN | 3.05 | - | - | -1.82 |
| 2025-06-02 | LTRN | 3.16 | - | - | -1.82 |
| 2025-06-03 | LTRN | 3.22 | - | - | -1.82 |
| 2025-06-04 | LTRN | 3.34 | - | - | -1.82 |
| 2025-06-05 | LTRN | 3.43 | - | - | -1.82 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-05-07 | LTRN | 0.00 | 1.78 | 3.40 |
| 2025-05-08 | LTRN | 0.00 | 1.78 | 3.40 |
| 2025-05-09 | LTRN | 0.00 | 1.78 | 3.40 |
| 2025-05-12 | LTRN | 0.00 | 1.59 | 3.17 |
| 2025-05-13 | LTRN | 0.00 | 1.59 | 3.17 |
| 2025-05-14 | LTRN | 0.00 | 1.59 | 3.17 |
| 2025-05-15 | LTRN | 0.00 | 1.59 | 3.17 |
| 2025-05-16 | LTRN | 0.00 | 1.59 | 3.17 |
| 2025-05-19 | LTRN | 0.00 | 1.39 | 3.17 |
| 2025-05-20 | LTRN | 0.00 | 1.39 | 3.17 |
| 2025-05-21 | LTRN | 0.00 | 1.39 | 3.17 |
| 2025-05-22 | LTRN | 0.00 | 1.39 | 3.17 |
| 2025-05-23 | LTRN | 0.00 | 1.39 | 3.17 |
| 2025-05-27 | LTRN | 0.00 | -4.87 | 3.17 |
| 2025-05-28 | LTRN | 0.00 | -4.87 | 3.17 |
| 2025-05-29 | LTRN | 0.00 | -4.87 | 3.17 |
| 2025-05-30 | LTRN | -3.92 | -4.87 | 3.17 |
| 2025-06-02 | LTRN | -3.93 | -4.87 | 3.17 |
| 2025-06-03 | LTRN | -3.93 | -4.87 | 3.17 |
| 2025-06-04 | LTRN | -4.05 | -4.87 | 3.14 |
| 2025-06-05 | LTRN | -4.04 | -4.87 | 3.14 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.48
Avg. EPS Est. Next Quarter
-0.44
Insider Transactions
-4.04
Institutional Transactions
-4.87
Beta
1.54
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
6
Growth Score
20
Sentiment Score
39
Actual DrawDown %
86.2
Max Drawdown 5-Year %
Target Price
22
P/E
Forward P/E
PEG
P/S
P/B
2.2
P/Free Cash Flow
EPS
-1.84
Average EPS Est. Cur. Y
-1.82
EPS Next Y. (Est.)
-1.55
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
1.21
Return on Equity vs Sector %
-142.5
Return on Equity vs Industry %
-124.7
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
0.16
EBIT Estimation
Lantern Pharma Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 24
Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
stock quote shares LTRN – Lantern Pharma Inc Stock Price stock today
news today LTRN – Lantern Pharma Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch LTRN – Lantern Pharma Inc yahoo finance google finance
stock history LTRN – Lantern Pharma Inc invest stock market
stock prices LTRN premarket after hours
ticker LTRN fair value insiders trading